The IGFBP5 Knockout KYSE-150 Polyclonal Cells provided by Ascent Research represent a CRISPR/Cas9-mediated gene-disrupted polyclonal population in the human esophageal squamous cell carcinoma line KYSE-150. This loss-of-function model enables comprehensive investigation of IGFBP5-dependent cellular processes by eliminating target gene expression across a mixed pool of edited cells, offering a robust system for studying heterogeneous responses.
The parental KYSE-150 cell line is derived from a poorly differentiated human esophageal squamous cell carcinoma, a highly aggressive malignancy with limited therapeutic options. KYSE-150 cells retain key characteristics of esophageal squamous carcinomas, including dysregulated growth signaling and metastatic potential, making them a widely employed model for esophageal cancer biology and preclinical drug evaluation.
IGFBP5 encodes an insulin-like growth factor-binding protein that tightly regulates the bioavailability of IGF1 and IGF2, thereby modulating IGF1R-mediated signaling cascades. By sequestering these ligands, IGFBP5 dampens activation of the PI3K-AKT and MAPK/ERK pathways, influencing downstream effectors such as AKT1, mTOR, MAPK1/3, cyclin D1, and BCL2 family members. Additionally, IGFBP5 exerts IGF-independent effects on apoptosis and migration. Its expression is transcriptionally regulated by TP53, TGFB1, and WNT3A, and it engages in extracellular interactions with vitronectin, PAI-1, LRP1, and the ALS complex, integrating cues from growth factor, stress, and matrix remodeling pathways.
In esophageal squamous cell carcinoma, IGFBP5 displays context-dependent tumor-suppressive or tumor-promoting activities, underscoring the value of a clean knockout model for dissecting its paradoxical roles. Disruption of IGFBP5 in KYSE-150 cells allows researchers to delineate how loss of this modulator alters IGF-driven proliferation, survival, and invasion, as well as p53-mediated apoptosis and senescence programs. This model is particularly relevant for exploring mechanisms of metastasis, extracellular matrix remodeling, and resistance to targeted therapies directed at the IGF1R axis.
The IGFBP5 Knockout KYSE-150 Polyclonal Cells are suited for a broad array of experimental workflows, including immunoblotting and RT-qPCR for validating target disruption and downstream signaling changes, proliferation (MTT, BrdU) and apoptosis (Annexin V/PI) assays, Transwell migration and invasion studies, and phospho-specific analyses of AKT (pAKT) and ERK (pERK). Additional applications encompass transcriptomic profiling via RNA-seq, co-immunoprecipitation for protein interaction mapping, and drug sensitivity screening to identify therapeutic vulnerabilities in the absence of IGFBP5. This knockout population provides a versatile platform for investigating IGFBP5 biology in esophageal cancer and beyond. For further information, please contact Ascent Research.
